Spyre Therapeutics (SYRE) Change in Receivables (2015 - 2023)
Spyre Therapeutics (SYRE) posted Change in Receivables of -$163000.0 for Q4 2023, up 89.01% on a QoQ basis from -$1.5 million in Q3 2023, and up 44.56% year-over-year from -$112757.6 in Q4 2022.
Spyre Therapeutics (SYRE) Change in Receivables (2015 - 2023) Analysis & Trends
Spyre Therapeutics' Change in Receivables history runs 7 years deep, the most recent figure standing at -$163000.0 for Q4 2023.
- Quarterly Change in Receivables rose 44.56% year-over-year to -$163000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$163000.0 (up 67.79% YoY) and the FY2023 annual result came in at -$375000.0, up 14.77% from the prior year.
- Change in Receivables was -$163000.0 for Q4 2023 at Spyre Therapeutics, up from -$1.5 million in the prior quarter.
- Across five years, Change in Receivables topped out at $21.5 million in Q1 2021 and bottomed at -$21.5 million in Q2 2021.
- A 3-year average of $0.0 and a median of -$45000.0 in 2023 frame the typical range for Change in Receivables.
- Peak annual rise in Change in Receivables reached 346.9% in 2023, while the deepest fall reached 880.53% in 2023.
- Spyre Therapeutics' Change in Receivables stood at $815000.0 in 2021, then plunged by 136.07% to -$294000.0 in 2022, then soared by 44.56% to -$163000.0 in 2023.
- Business Quant data shows SYRE's Change in Receivables at -$163000.0 in Q4 2023, -$1.5 million in Q3 2023, and $1.3 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -163,000.00 |
| Dec 31, 2023 | -163,000.00 |
| Sep 30, 2023 | -1.48 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | -45,000.00 |
| Mar 31, 2023 | -45,000.00 |
| Dec 31, 2022 | -294,000.00 |
| Dec 31, 2022 | -294,000.00 |
| Sep 30, 2022 | 190,000.00 |
| Sep 30, 2022 | 190,000.00 |
| Jun 30, 2022 | -533,000.00 |
| Jun 30, 2022 | -533,000.00 |
| Mar 31, 2022 | 197,000.00 |
| Mar 31, 2022 | 197,000.00 |
| Dec 31, 2021 | 815,000.00 |
| Dec 31, 2021 | 815,000.00 |
| Jun 30, 2021 | -21.50 Mn |
| Jun 30, 2021 | -21.50 Mn |